Literature DB >> 8943428

Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies.

P B Yu1, Z E Holzknecht, D Bruno, W Parker, J L Platt.   

Abstract

The most abundant natural IgG Abs in human serum are thought to be Abs specific for Gal alpha1-3Gal, a carbohydrate expressed in lower mammals. IgG Abs specific for Gal alpha1-3Gal have been postulated to contribute to host defense and to participate in the rejection of interspecies organ grafts. Our previous studies indicated, however, that IgM and not IgG anti-Gal alpha1-3Gal Abs activate complement on foreign surfaces, and thus the physiologic role of IgG anti-Gal alpha1-3Gal remains uncertain. We tested whether the IgG anti-Gal alpha1-3Gal in a human serum might in fact compete with IgM for binding and thus modulate complement fixation by IgM. Several lines of evidence suggested such competition might occur. First, the functional avidity of IgG and IgM for Gal alpha1-3Gal on cell surfaces were nearly within the same order of magnitude, and in some sera the molar concentrations of IgG and IgM anti-Gal alpha1-3Gal were comparable. Second, binding of human IgM to Gal alpha1-3Gal on cell surfaces was inversely correlated with the concentration of IgG anti-Gal alpha1-3Gal in serum. Third, combination of IgG and IgM Abs specific for Gal alpha1-3Gal demonstrated direct competition for binding. The presence of IgG anti-Gal alpha1-3Gal, which was predominantly IgG2, attenuated by up to 80% the fixation of C1q mediated by IgM, presumably by competing for antigenic sites recognized by IgM Abs that fix complement. Thus, IgG Abs specific for Gal alpha1-3Gal modulate complement activation by IgM specific for that structure and might in this way modulate the consequences that ensue when human blood is brought into contact with foreign organisms or xenogenic cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943428

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues.

Authors:  P B Yu; W Parker; M L Everett; I J Fox; J L Platt
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

Review 2.  Donor specific antibodies after transplantation.

Authors:  Jeffrey L Platt; Marilia Cascalho
Journal:  Pediatr Transplant       Date:  2011-03-29

Review 3.  Accommodation of grafts: implications for health and disease.

Authors:  Amy H Tang; Jeffrey L Platt
Journal:  Hum Immunol       Date:  2007-05-15       Impact factor: 2.850

Review 4.  Immune response to biologic scaffold materials.

Authors:  Stephen F Badylak; Thomas W Gilbert
Journal:  Semin Immunol       Date:  2008-02-20       Impact factor: 11.130

Review 5.  Accommodation in organ transplantation.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Curr Opin Organ Transplant       Date:  2008-04       Impact factor: 2.640

Review 6.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 7.  B cells in transplant tolerance and rejection: friends or foes?

Authors:  Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun
Journal:  Transpl Int       Date:  2020-01       Impact factor: 3.782

8.  Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

Authors:  J G Schoenecker; R K Hauck; M C Mercer; W Parker; J H Lawson
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

Review 9.  α-Gal Nanoparticles in Wound and Burn Healing Acceleration.

Authors:  Uri Galili
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-03-01       Impact factor: 4.730

Review 10.  Escaping from rejection.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Transplantation       Date:  2009-12-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.